Evidence map›Paper›PMID 38457091›Full record

SynthesisJournal of neuro-oncology2024

Fractionated stereotactic radiotherapy in craniopharyngiomas: A systematic review and single arm meta-analysis.

Lucca B Palavani, Guilherme Melo Silva, Pedro G L B Borges, Márcio Yuri Ferreira, Marcelo Porto Sousa, Marianna G H S J Leite, Leonardo de Barros Oliveira, Sávio Batista, Raphael Bertani, Allan Dias Polverini and 2 more

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Journal of neuro-oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Lucca B PalavaniMax Planck University Center, Indaiatuba, SP, Brazil.
Guilherme Melo SilvaFederal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
Pedro G L B BorgesTechnical-Educational Foundation Souza Marques, Rio de Janeiro, RJ, Brazil.
Márcio Yuri FerreiraPostgraduate Program in Translational Surgery of Federal University of São Paulo, São Paulo, SP, Brazil.
Marcelo Porto SousaFederal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
Marianna G H S J LeiteFaculty of Medicine Santa Marcelina, São Paulo, SP, Brazil.
Leonardo de Barros OliveiraDepartment of Neurosurgery, State University of Ponta Grossa, Ponta Grossa, PR, Brazil. leobarrosoliveira09@gmail.com.
Sávio BatistaFederal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
Raphael BertaniDepartment of Neurosurgery, University of São Paulo, São Paulo, SP, Brazil.
Allan Dias PolveriniNeurosurgical Oncology Division, Barretos Cancer Hospital, Barretos, SP, Brazil.
André Beer-FurlanDepartment of Neuro-Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Wellingson PaivaDepartment of Neurosurgery, University of São Paulo, São Paulo, SP, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionNumerous studies have demonstrated Fractionated Stereotactic Radiotherapy's (FSRT) effectiveness in tumor control post-resection for craniopharyngiomas. Nevertheless, past literature has presented conflicting findings particularly regarding endocrine and visual function outcomes. This study aims to elucidate FSRT's efficacy and safety for this population.

methodsAdhering to PRISMA, a systematic review and meta-analyses was conducted. Included studies had to report the effects of FSRT for treating craniopharyngiomas in a sample greater than four patients, addressing at least one of the outcomes of interest: improvement in visual acuity or field, new-onset hypopituitarism, effectiveness, and tumor progression. Relative risk with 95% confidence intervals were used to assess the outcomes.

resultsAfter retrieving a total of 1292 studies, 10 articles met the predefined criteria and thus were finally selected, amounting to a total of 256 patients. The improvement in visual acuity was estimated at 45% (95% CI: 6-83%), while the improvement in the visual field was 22% (95% CI: 0-51%). Regarding endocrine function, the new-onset hypopituitarism rate was found to be 5% (95% CI: 0-11%). Relative to FSRT effectiveness, the pooled estimate of the complete tumor response rate was 17% (95% CI: 4-30%), and the tumor progression rate was 7% (95% CI: 1-13%). Also, a 3-year progression-free survival rate of 98% (95% CI: 95-100%) was obtained.

conclusionDespite limitations and risks, FSRT shows promise as a viable therapeutic option for craniopharyngiomas, offering notable benefits for visual functions and tumor control. Further research is required to better understand the associated risks, benefits, and clinical utility.

Indexed as

CraniopharyngiomaPituitary NeoplasmsRadiosurgeryDose Fractionation, RadiationHumansCraniopharyngiomaFractionated stereotactic radiotherapyFSRTMeta-analysisRadiotherapy

Identifiers

PMID38457091

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.